Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00682552|
Recruitment Status : Terminated
First Posted : May 22, 2008
Last Update Posted : August 28, 2014
|Condition or disease||Intervention/treatment||Phase|
|Cervical Intraepithelial Neoplasia||Procedure: A cervico-vaginal cervical smear||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||February 2013|
|Actual Study Completion Date :||February 2013|
A cervico-vaginal cervical smear will be realized before every colposcopique examination.
A new cervical taking for the search(research) and the detection of the HPV 16 and 18 will be realized.
Procedure: A cervico-vaginal cervical smear
12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
- The detection and the quantification of the DNA of the human oncogènes papillomavirus of type 16 and 18 [ Time Frame: 48 months ]
- The detection of the markers of the integration of the genome of the human oncogenes papillomavirus (targeted at the gene E2) [ Time Frame: 48 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00682552
|Hopital Nord- Service de gynécologie-obstétrique|
|Marseille, France, 13015|
|Principal Investigator:||Xavier CARCOPINO, MD||Assistance Publique des Hopitaux de Marseille|